Status:
COMPLETED
The Effects of Probiotic Supplementation on State and Trait Stress, Anxiety, and Depression Symptoms in Stressed Adults
Lead Sponsor:
University of Colorado, Boulder
Conditions:
Anxiety Symptoms
Perceived Stress
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
The goal of this randomized controlled trial is to learn if supplementation with the probiotic Lactobacillus reuteri DSM 17938 can reduce levels of trait and state perceived stress, anxiety, and depre...
Eligibility Criteria
Inclusion
- age 18 - 45
- scoring 14+ on the perceived stress scale-10 indicating medium stress or higher
- ability to provide informed consent
- willingness not to take probiotic supplements (pills, tablets, oils, etc.) other than the product provided in the clinical study until all study procedures are completed
- own a smartphone and are willing to receive study materials and complete study procedures by text
Exclusion
- a history of gastrointestinal discomfort or surgery, urinary incontinence, cancer, toxic shock syndrome, frequent diarrhea, vital signs outside of the acceptable range (i.e., blood pressure \>160/100, oral temperature \>100°F, pulse \>100), heart disease, heart attack, lung/respiratory disease, any pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality (i.e. a medical diagnosis related to lungs, heart, stomach/intestines, liver, or kidneys), HIV, Hepatitis B, Hepatitis C, bipolar disorder, psychosis, or confirmed or suspected immunosuppression or immunodeficiency
- current (past month) alcohol or substance abuse or dependence (score of 2+ on the UNCOPE)
- consistent (e.g., 5x/week or greater) probiotic supplementation within the last month, including probiotic food products such as yogurt
- receiving antibiotics within the last month
- receiving medications that interfere with gut motility (opiates, loperamide, stool softeners)
- use of systemic antibiotics, antifungals, antivirals, or antiparasitics (intravenous, intramuscular, or oral)
- use of oral, intravenous, intramuscular, nasal or inhaled corticosteroids
- use of cytokines or cytokine inhibitors
- use of methotrexate or immunosuppressive cytotoxic agents
- receiving immunosuppressive drugs/medications or treatment including antineoplastic therapy, post-transplantation immunosuppressive therapy, and/or radiation therapy
- participation in conflicting interventional research protocol
- unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in their diet
- female who is pregnant or lactating or reports expecting to get pregnant during the course of the study
- currently involved in the criminal justice system as a prisoner or ward of the state
Key Trial Info
Start Date :
February 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07216729
Start Date
February 20 2023
End Date
June 1 2024
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Boulder, Muenzinger Psychology Building
Boulder, Colorado, United States, 80309